Risk factors

The Trust holds only ether and cash, exposing investors to extreme volatility and lack of diversification in digital assets. The Trust is passively managed, cannot engage in staking, and suffers a declining asset value per share from the Sponsor Fee. Trading and index risks, regulatory uncertainties, and lack of in-kind creation and redemption further threaten share value.

Accumulated deficit reached $1.4 billion as of December 31, 2024, with no approved products or commercial revenues.

Company is a Cayman Islands blank check firm targeting the TMT industry in Asia, particularly China.

Concentrated customer base creates revenue dependency on JPMorgan Chase and American Express, representing 63% of net sales in 2024. Heavy reliance on external management by Resolute Holdings under a non-fiduciary contract. Substantial debt load of $197.5 million with variable SOFR interest rates.

Grail faces massive net losses, reaching $2.0 billion in fiscal 2024, driven by research and commercialization of its Galleri cancer test.

Hydrofarm faces significant exposure to federal cannabis illegality, supply chain disruptions, international tariffs, and restructuring execution risks.

Hycroft Mining faces going concern doubts after halting commercial production and relying solely on the Hycroft Mine. Substantial debt and credit agreement restrictions threaten operations without additional capital. Gold and silver price volatility directly impacts potential revenues and financial health.

The Trust's risks are dominated by bitcoin price volatility, blockchain forks, and custody security threats. Regulatory uncertainty regarding digital assets and reliance on cash creations heavily impact the Trust.

The risk factors are dominated by the heavy investment in the Xvantage digital platform and legacy ERP systems. Operations face strong pressures from narrow gross margins, vendor concentration, and global macroeconomic volatility. Financial risks include substantial variable-rate debt, credit exposure on customer accounts, and identified material weaknesses in internal controls.

Orthopediatrics Corp faces ongoing operating losses with an accumulated deficit of $235.6 million as of December 31, 2024. Revenue grew to $204.7 million in 2024, driven by pediatric orthopedic products sold across domestic and international markets.

Customer access to floor plan financing and credit availability heavily dictates product demand and purchasing volume. International operations in Europe face manufacturing, tariff, and geopolitical uncertainties. Substantial debt of $70.0 million under our credit facility imposes operating restrictions.

Substantially all Coal Mining profits rely on long-term contracts vulnerable to anti-coal activities and regulations. NAMining growth faces geographic concentration risk with over 75 percent of quarries in Florida. Minerals are depleting assets requiring ongoing acquisitions or third-party exploration to maintain royalty income.